Breo 2018 report




Published July 2019 • 24 Pages

The 5 Key Questions Addressed by this Report:

  • How many physicians were reached by Breo through reportable promotional activity in 2018 and how does this compare to its peer set in the Asthma and Chronic Obstructive Pulmonary Disease markets?
  • What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
  • How does GSK’s depth of coverage vary within key specialties (e.g., Family Medicine, Internal Medicine, Pulmonology, and Allergy/Immunology) and how does this compare to its peers and the overall set of rep-accessible physicians?
  • How often are physicians receiving paid meals for Breo throughout the year (e.g., monthly, quarterly, annually)?
  • Who were the most frequent meal recipients and top paid speakers for Breo in 2018?

Data Sources and Methodology:

  • MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, over 5 years of longitudinal data is available – covering payments to more than 1,000,000 U.S. healthcare professionals.
  • Over 60,900 paid interactions across 21,100 physicians made on behalf of Breo were carefully examined to support our analysis. In addition, interaction data from 24 peer products (e.g. Advair, Anoro, Asmanex, Bevespi, Brovana, Cinqair, Dulera, Dupixent, Fasenra, Flovent, Incruse, Lonhala Magnair, Nucala, Perforomist, Qvar, Seebri Neohaler, Spiriva, Stiolto, Symbicort, Trelegy Ellipta, Tudorza, Utibron, Xolair, and Yupelri ) was leveraged to provide benchmarking and market insights.